International Clinical Trials Day
Today on Clinical Trials Day, Bold Therapeutics proudly stands alongside colleagues, partners, & patients in recognizing the vital role of clinical research.
Read more
Today on Clinical Trials Day, Bold Therapeutics proudly stands alongside colleagues, partners, & patients in recognizing the vital role of clinical research.
Read more
04-30-2025
Bold Therapeutics Sr. Director, Mark Bazett, PhD, is presenting a poster on BOLD-100s potent neuroprotective properties later today at AACR 2025 Annual Meeting.
04-28-2025
Bold Therapeutics Sr. Director, Mark Bazett, PhD, will be presenting on BOLD-100s potent neuroprotective properties at AACR Annual Meeting 2025.
06-24-2024
Bold Therapeutics has been invited to speak at the 2024 Metals in Medicine Gordon Research Conference.
06-03-2024
Bold Therapeutics announced positive Phase 2 result for BOLD-100 in the treatment of advanced metastatic biliary tract cancer and gastric cancer at ASCO 2024.
04-04-2024
Bold Therapeutics announces that Dr. Do-Youn Oh’s group at Seoul National University College of Medicine will present at the AACR Meeting, April 5-10, 2024.
01-23-2024
Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Colorectal Cancer at ASCO GI 2024.
09-22-2023
Bold Therapeutics Selected as a 2023 Company to Watch by Life Sciences British Columbia (LSBC).
06-07-2023
Bold Therapeutics announced positive interim results in advanced gastric and biliary tract cancer at the 2023 ASCO Annual Meeting.
06-01-2023
Bold Therapeutics will be presenting positive interim results in advanced gastric and biliary tract cancer at 2023 (ASCO) Annual Meeting on June 2-6.
04-18-2023
Bold Therapeutics is excited to share interim Phase 2 data for BOLD-100 in the treatment of advanced colorectal cancer.
04-13-2023
Bold Therapeutics is excited to present robustly positive interim Phase 2 data in metastatic colorectal cancer at the upcoming AACR conference.
04-13-2023
Bold Therapeutics is excited to present robustly positive interim Phase 2 data in metastatic colorectal cancer at the upcoming AACR conference.
10-14-2022
Bold Therapeutics announces that they will be attending and presenting at BIO-Europe 2022 and BIO-Europe 2022 Virtual Conferences.
06-27-2022
Bold Therapeutics is excited to share compelling early efficacy data on BOLD-100 at the 2022 Metals in Medicine Gordon Research Conference.
05-10-2022
Bold Therapeutics is pleased to have been invited to present at Bio Korea 2022 as part of the Canadian trade delegation.
04-06-2022
Bold Therapeutics announced that it will present research supporting the use of BOLD-100 at the AACR Annual Meeting 2022 on April 8-13, 2022 in New Orleans.
04-04-2022
Bold Therapeutics is excited to announce second place in the Innovator’s Pitch Challenge at the Digital Redefining Early-Stage Investments Conference.
03-10-2022
Bold Therapeutics successfully completed Phase 1b of its oncology trial of BOLD-100 combined with FOLFOX in the treatment of advanced gastrointestinal cancers.
01-13-2022
Bold Therapeutics announces an extension of the option agreement with Hana Pharm for development and commercialization rights to BOLD-100 in South Korea.
09-16-2021
Bold Therapeutics has demonstrated potent anti-tumor activity in combination with a PD-1 checkpoint inhibitor in an in vivo model of colorectal cancer.